BioMarin Pharmaceutical (NASDAQ:BMRN) : On Wednesday, The money flowed into the BioMarin Pharmaceutical (NASDAQ:BMRN) stock with an uptick to downtick ratio was recorded at 1.28. Transactions worth $7.95 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $6.22 million. The total money flow into the stock was $1.73 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $0.01 million of block transactions on upticks. The total money flow in block trades was $0.01 million. In terms of price action, BioMarin Pharmaceutical (NASDAQ:BMRN) traded down $0.06 during the session at $79.43. Compared to the previous days closing, the stock was down only by -0.07%. For the week, the stock is 3.15%, over previous weeks closing.
In an insider trading activity, The director, of Biomarin Pharmaceutical Inc, Lawlis V Bryan had unloaded 550 shares at $82.77 per share in a transaction on June 20, 2016. The total value of transaction was $45,524. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 2.5% of BioMarin Pharmaceutical shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -11.8% . During last six month period, the net percent change held by insiders has seen a change of -3.94%.
The company shares have dropped -41.86% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $151.75 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $84.38 and the 200 Day Moving Average price is recorded at $85.22. BioMarin Pharmaceutical (NASDAQ:BMRN): The stock opened at $80.52 on Wednesday but the bulls could not build on the opening and the stock topped out at $81.08 for the day. The stock traded down to $78.20 during the day, due to lack of any buying support eventually closed down at $78.37 with a loss of -1.41% for the day. The stock had closed at $79.49 on the previous day. The total traded volume was 2,142,117 shares.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).